0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Korea Hemophilia Treatment Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

Korea Hemophilia Treatment Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00 – $ 8,900.00

Korea Hemophilia Treatment Market: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment Type (Plasma derived coagulation factor concentrate, Recombinant coagulation factor concentrates, Desmopressin, Antifibrinolytic agents, Gene Therapy), By End User(Hospitals & Clinics, Research Organizations, Others) and Geography

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category: Tag:
Report

Description

Korea Hemophilia Treatment Market size is valued at USD x million in 2021 and is expected to reach a value of USD x million by 2028, growing at a CAGR of x% during the forecast period 2022 to 2028. The market provides a detailed overview of the Korea hemophilia treatment market and that can be segmented by type, treatment type, and end-user. By type, the Korea hemophilia treatment market has been segmented into hemophilia A, hemophilia B and hemophilia C. The hemophilia A segment is likely to be the largest and fastest-growing segment in terms of type. Based on treatment type, the Korean hemophilia treatment market is segmented into plasma-derived coagulation factor concentrate, recombinant coagulation factor concentrates, desmopressin, antifibrinolytic agents, and gene therapy. The recombinant coagulation factor concentrates segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on end-users, the Korean hemophilia treatment market is segmented into hospitals & clinics, research organizations, and others. The research organizations segment accounts for the largest share in 2021. The hospitals & clinics segment has the second-largest share during the forecast period 2021-2028.

Korea Hemophilia Treatment Market

MARKET SUMMARY
-
X
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– X
  • Largest Market– Korea
Korea Hemophilia

Treatment Market

  • Korea Hemophilia Treatment Market report gives a comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • Korea Hemophilia Treatment Market is segmented based on type, treatment type, end-user and geography.
Market Leaders
  • Pfizer Inc
  • Biogen Idec Inc
  • CSL Ltd
  • Baxter International Inc
  • Novo Nordisk
Korea Hemophilia Treatment Market

Drivers and Restraints

The market is expected to develop due to the rising prevalence of bleeding diseases and their increasing severity as a result of genetic evolution. It is also envisaged that this will help patients manage their budgets and gain access to new items. To better the monitoring of such diseases and other linked problems, new approaches have been created. Furthermore, in recent years, public awareness of the necessity of early-stage diagnosis and treatment, as well as its potential impact, has risen dramatically, driving demand for a product that would significantly approximate market revenue.

Korea Hemophilia Treatment Market Regional Analysis

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Features of the Report

  • The Korea hemophilia treatment market report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Korea hemophilia treatment market report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Korea hemophilia treatment market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Korea hemophilia treatment market report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Korea hemophilia treatment market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Korea Hemophilia Treatment Market Segmentation

segmentation-block-image

Type

    • Hemophilia A,
    • Hemophilia B
    • Hemophilia C
segmentation-block-image

Treatment Type

    • Plasma derived coagulation factor concentrate
    • Recombinant coagulation factor concentrates
    • Desmopressin, Antifibrinolytic agents
    • Gene Therapy
segmentation-block-image

End User

    • Hospitals & Clinics,
    • Research Organizations
    • Others
segmentation-block-image

Geography

    • North America
    • Europe
    • Asia Pacifi
    • Latin America
    • Middle East and Africa.
Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Report

Table Of Content

1. Executive Summary
2. Korea Hemophilia Treatment Market Introduction
2.1. Korea Hemophilia Treatment Market – Taxonomy
2.2. Korea Hemophilia Treatment Market –Definitions
2.2.1. Type
2.2.2. Treatment Type
2.2.3. End User
3. Korea Hemophilia Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Korea Hemophilia Treatment Market Dynamic Factors – Impact Analysis
3.6. Korea Hemophilia Treatment Market – Competition Landscape
4. Korea Hemophilia Treatment Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Korea Hemophilia Treatment Market, By Type, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 
5.1. Hemophilia A
5.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Hemophilia B
5.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Hemophilia C
5.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Korea Hemophilia Treatment Market Forecast, By Treatment Type, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 
6.1. Plasma derived coagulation factor concentrate
6.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Recombinant coagulation factor concentrates
6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Desmopressin
6.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Antifibrinolytic agents
6.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Gene Therapy
6.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Korea Hemophilia Treatment Market Forecast, By End User, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 
7.1. Hospitals & Clinics
7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Research Organizations
7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Competition Landscape 
8.1. Strategic Dashboard of Top Market Players
8.2. Company Profiles (Introduction, Financial Analysis, Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
8.2.1. Pfizer Inc
8.2.2. Biogen Idec Inc
8.2.3. CSL Ltd
8.2.4. Baxter International Inc
8.2.5. Novo Nordisk
8.2.6. KedrionBayer AG
8.2.7. Grifols SA
8.2.8. Bayer AG
9. Research Methodology
10. Key Assumptions and Acronyms
Report

Company Profile

  • Pfizer Inc
  • Biogen Idec Inc
  • CSL Ltd
  • Baxter International Inc
  • Novo Nordisk
  • KedrionBayer AG
  • Grifols SA
  • Bayer AG

Description

Korea Hemophilia Treatment Market size is valued at USD x million in 2021 and is expected to reach a value of USD x million by 2028, growing at a CAGR of x% during the forecast period 2022 to 2028. The market provides a detailed overview of the Korea hemophilia treatment market and that can be segmented by type, treatment type, and end-user. By type, the Korea hemophilia treatment market has been segmented into hemophilia A, hemophilia B and hemophilia C. The hemophilia A segment is likely to be the largest and fastest-growing segment in terms of type. Based on treatment type, the Korean hemophilia treatment market is segmented into plasma-derived coagulation factor concentrate, recombinant coagulation factor concentrates, desmopressin, antifibrinolytic agents, and gene therapy. The recombinant coagulation factor concentrates segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on end-users, the Korean hemophilia treatment market is segmented into hospitals & clinics, research organizations, and others. The research organizations segment accounts for the largest share in 2021. The hospitals & clinics segment has the second-largest share during the forecast period 2021-2028.

Reviews

There are no reviews yet.

Be the first to review “Korea Hemophilia Treatment Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+